About BlueSphere Bio
BlueSphere Bio is a Healthcare company based in Pittsburgh (United States) founded in 2017 by Constantinos Panousis, Warren Shlomchik, and Mark Shlomchik. T-cell therapies for cancer treatment are developed using proprietary technology. BlueSphere Bio has raised $45.64 million across 1 funding round. The company has 21 employees. Its chief executive, as recorded, is David Apelian. BlueSphere Bio offers products and services including TCX-101 and TCX-102. Its focus areas include Life Sciences, Immunotherapy, Adoptive Cell Therapy and T-Cell. Its legal entity is BLUESPHERE BIO, INC. Its competitors include Moderna, BeiGene and Incyte; 2 of its 3 listed competitors have raised funding.
Company details
BlueSphere Bio was founded in 2017 in Pittsburgh, United States, within the biotechnology sector focused on oncology. Personalized T-cell treatments are provided through the proprietary TCXpress platform, by which the patients immune system is harnessed to target cancer cells specifically. Operations center on advancing these therapies for clinical application, with a team led by co-founders and CEO David Apelian.
- Headquarters Pittsburgh, United States
- Employees 21
- Founders Constantinos Panousis, Warren Shlomchik, Mark Shlomchik
- SectorsHealthcare
- Email••••••••
- Website bluespherebio.com
- Social LinkedIn X
- Legal Name Bluesphere Bio, Inc.
- Total Equity Funding$45.64M (USD)
in 1 rounds
- Latest Funding Round$45.64M (USD), Series C
Dec 2020
- Employee Count21
Products & Services of BlueSphere Bio
BlueSphere Bio offers a comprehensive portfolio of products and services, including TCX-101 and TCX-102.
TCR-based treatment for hematologic malignancies
TCR-based treatment for solid tumors
Funding Insights of BlueSphere Bio
BlueSphere Bio has successfully raised a total of $45.64M through 1 strategic funding round. The most recent funding activity was a Series C round of $45.64 million completed in December 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $45.64M
- Total Rounds 1
- Last Round Series C — $45.64M
- First Round $45.64M
(Dec 2020)
All 1 funding rounds of BlueSphere Bio with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2020 | $45.64M | Series C | – | – | – |
People of BlueSphere Bio
25 people are tracked at BlueSphere Bio (15 in leadership, 3 in board & advisors, 7 in team); the tracked headcount is 21.
| Name | Role | Group |
|---|---|---|
Constantinos Panousis | Co-Founder | Leadership |
Warren Shlomchik | Co-Founder | Leadership |
Mark Shlomchik | Co-Founder | Leadership |
David Apelian | CEO | Leadership |
Brooke Helfer | Senior Director Of Product Development | Leadership |
Keir J. LoIacono, Esq. | Chief Executive Officer | Leadership |
Paola Sette | Associate Director | Leadership |
Jason M. Laura | Vice President, Human Resources | Leadership |
Tim Mayall | Senior Vice President, Translational Sciences | Leadership |
Kim Jaffe | Chief Business Officer | Leadership |
Robert Keefe | Chief Development Officer Bluesphere Bio | Leadership |
James (Joe) Akin | Executive Director Business Development | Leadership |
Stephanie Stras | Associate Director, Lab Automation | Leadership |
Erkut Bahceci | Chief Medical Officer | Leadership |
Yingzhe Li | Vice President, Research & Development | Leadership |
Jeanne Cunicelli | Director | Board & advisors |
Jonathan Peacock | Director | Board & advisors |
Alan Korman | Director | Board & advisors |
Jennifer Zerbato, PhD | Scientist | Team |
Lauren Van Der Kraak, PhD | Scientist | Team |
5 more people are available in the full profile.
Complete people profiles for BlueSphere Bio
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of BlueSphere Bio
2 dated milestones of BlueSphere Bio across 3 years, from founding to its latest funding, stage changes and deals.
- Founded BlueSphere Bio is founded.
- Funding First funding round of $45.6M.
Competitors of BlueSphere Bio
BlueSphere Bio has 3 listed competitors in our database, 2 of them funded. They include Moderna, BeiGene and Incyte.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. | |
| incyte.com | 1991 | Wilmington, United States | 1,387 | Small molecules are developed for cancer and skin disease treatments. |
Detailed competitors of BlueSphere Bio
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of BlueSphere Bio
The website of BlueSphere Bio (bluespherebio.com) receives about 2.5K visits a month.
- Monthly visits2.5K
▼ 8.5% vs previous month
Websites whose visitors overlap most with BlueSphere Bio. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| novasenta.com | 100% | 2.4K | #6,002,810 | View details | |
| plexision.com | 98% | 3.2K | #5,846,553 | View details | |
| ecmtherapeutics.com | 98% | 2.6K | #6,640,901 | View details | |
| peptilogics.com | 98% | 2.1K | #8,263,579 | View details | |
pittbioforge.org | pittbioforge.org | 95% | #6,533,171 | – | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 12 similar websites and full traffic analytics for BlueSphere Bio
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 12 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as BlueSphere Bio (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Bluesphere Bio
Complete news archive for BlueSphere Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about BlueSphere Bio
BlueSphere Bio was founded in 2017 and raised its 1st funding round 3 years after it was founded.
BlueSphere Bio is headquartered in Pittsburgh, United States. It is registered at Pittsburgh, Pennsylvania, United States.
David Apelian is the CEO of BlueSphere Bio, as recorded in our data.
BlueSphere Bio is a funded company, having raised a total of $45.64M across 1 funding round to date. The company's 1st funding round was a Series C of $45.64M, raised on Dec 2020.
BlueSphere Bio has 21 employees.
BlueSphere Bio was founded in 2017 in Pittsburgh, United States, within the biotechnology sector focused on oncology. Personalized T-cell treatments are provided through the proprietary TCXpress platform, by which the patients immune system is harnessed to target cancer cells specifically. Operations center on advancing these therapies for clinical application, with a team led by co-founders and CEO David Apelian.
BlueSphere Bio offers TCX-101 and TCX-102.
BlueSphere Bio operates through Bluesphere Bio, Inc..